Targeting β-Amyloid Pathology in Alzheimer's Disease with Aβ Immunotherapy

Neurotherapeutics

Volumn 5, Issue 3, 2008, Pages 415-420

  Nitsch, Roger M ^a   Hock, Christoph ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

APP; clinical trial; Humanized monoclonal antibody; neurodegeneration; passive immunization; vaccination

Indexed keywords

AAB 002; ACC 001; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BAPINEUZUMAB; CAD 106; GAMMAGUARD; GSK 933776A; IMMUNOGLOBULIN G; LY 2062430; MONOCLONAL ANTIBODY; OLIGOMER; PF 04360365; PF 4360365; PLACEBO; POLYSORBATE 80; QS 21; R 1450; V 950;

ALZHEIMER DISEASE; ANTIBODY TITER; ARTICLE; BLOOD BRAIN BARRIER; BRAIN SIZE; CLINICAL TRIAL; CROSS REACTION; DEMENTIA; DISEASE COURSE; DRUG SAFETY; DRUG TARGETING; EDEMA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MENINGOENCEPHALITIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; SUBACUTE ASEPTIC MENINGOENCEPHALITIS; VACCINATION; VASOGENIC EDEMA;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY;

EID: 46749113799     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.05.013     Document Type: Article

References (61)

1. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
2. Janus C., Pearson J., McLaurin J., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
3. Weiner H.L., Lemere C.A., Maron R., et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48 (2000) 567-579
4. Lemere C.A., Maron R., Selkoe D.J., and Weiner H.L. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 20 (2001) 705-711
5. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., and Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159 (2001) 439-447
6. Lemere C.A., Beierschmitt A., Iglesias M., et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165 (2004) 283-297
7. Weiner H.L., and Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 6 (2006) 404-416
8. Schenk D., Hagen M., and Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 16 (2004) 599-606
9. Solomon B. Antibody-mediated immunotherapy for Alzheimer's disease. Curr Opin Investig Drugs 8 (2007) 519-524
10. Brody D.L., and Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) Mar 19; [Epub ahead of print]
11. Bard F., Cannon C., Barbour R., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6 (2000) 916-919
12. Bacskai B.J., Kajdasz S.T., Christie R.H., et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7 (2001) 369-372
13. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98 (2001) 8850-8855
14. Bacskai B.J., Kajdasz S.T., McLellan M.E., et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 22 (2002) 7873-7878
15. Das P., Howard V., Loosbrock N., Dickson D., Murphy M.P., and Golde T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 23 (2003) 8532-8538
16. Wilcock D.M., Rojiani A., Rosenthal A., et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24 (2004) 6144-6151
17. Wilcock D.M., Rojiani A., Rosenthal A., et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1 (2004) 24
18. Boyett K.W., DiCarlo G., Jantzen P.T., et al. Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem Res 28 (2003) 83-93
19. Wilcock D.M., Jantzen P.T., Li Q., Morgan D., and Gordon M.N. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144 (2007) 950-960
20. Lombardo J.A., Stern E.A., McLellan M.E., et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 23 (2003) 10879-10883
21. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., and LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 (2004) 321-332
22. Klyubin I., Walsh D.M., Lemere C.A., et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11 (2005) 556-561
23. Knobloch M., Farinelli M., Konietzko U., Nitsch R.M., and Mansuy I.M. Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci 27 (2007) 7648-7653
24. Bales K.R., Tzavara E.T., Wu S., et al. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J Clin Invest 116 (2006) 825-832
25. Mohajeri M.H., Saini K., Schultz J.G., Wollmer M.A., Hock C., and Nitsch R.M. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 277 (2002) 33012-33017
26. Morgan D., Diamond D.M., Gottschall P.E., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
27. Sigurdsson E.M., Knudsen E., Asuni A., et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 24 (2004) 6277-6282
28. Chen G., Chen K.S., Kobayashi D., et al. Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J Neurosci 27 (2007) 2654-2662
29. Pfeifer M., Boncristiano S., Bondolfi L., et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298 (2002) 1379
30. Racke M.M., Boone L.I., Hepburn D.L., et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25 (2005) 629-636
31. Taguchi H., Planque S., Nishiyama Y., et al. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 283 (2008) 4714-4722
32. Bayer A.J., Bullock R., Jones R.W., et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64 (2005) 94-101
33. Pride M., Seubert P., Grundman M., Hagen M., Eldridge J., and Black R.S. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 5 (2008) 194-196
34. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9 (2003) 448-452
35. Orgogozo J.M., Gilman S., Dartigues J.F., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
36. Hock C., Konietzko U., Papassotiropoulos A., et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8 (2002) 1270-1275
37. Gilman S., Koller M., Black R.S., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
38. Hock C., Konietzko U., Streffer J.R., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
39. Black RS SR, Kirby L, Safirstein B, Motter R, Pallay A. A single ascending dose study of bapineuzumab, a humanized monoclonal antibody to Aβ, in AD. Paper presented at: 9th International Symposium on Alzheimer Therapy; July 19, 2006; Geneva, Switzerland.
40. Harrison J., Minassian S.L., Jenkins L., Black R.S., Koller M., and Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64 (2007) 1323-1329
41. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14 (2004) 11-20
42. Masliah E., Hansen L., Adame A., et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 (2005) 129-131
43. Bombois S., Maurage C.A., Gompel M., et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol 64 (2007) 583-587
44. Patton R.L., Kalback W.M., Esh C.L., et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 169 (2006) 1048-1063
45. Wilcock D.M., Alamed J., Gottschall P.E., et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26 (2006) 5340-5346
46. Relkin N.R. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease. Expert Rev Neurother 7 (2007) 735-748
47. Prada C.M., Garcia-Alloza M., Betensky R.A., et al. Antibody-mediated clearance of amyloid-beta peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J Neurosci 27 (2007) 1973-1980
48. Fox N.C., Black R.S., Gilman S., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (2005) 1563-1572
49. Nicoll J.A., Barton E., Boche D., et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65 (2006) 1040-1048
50. Gotz J., Chen F., van Dorpe J., and Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293 (2001) 1491-1495
51. Ferrari A., Hoerndli F., Baechi T., Nitsch R.M., and Gotz J. beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem 278 (2003) 40162-40168
52. King M.E., Kan H.M., Baas P.W., Erisir A., Glabe C.G., and Bloom G.S. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 175 (2006) 541-546
53. Lewis J., Dickson D.W., Lin W.L., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
54. Oddo S., Caccamo A., Tran L., et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 281 (2006) 1599-1604
55. Lesne S., Koh M.T., Kotilinek L., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
56. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res (2008)
57. Walsh D.M., Klyubin I., Fadeeva J.V., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
58. Walsh D.M., and Selkoe D.J. A beta oligomers - a decade of discovery. J Neurochem 101 (2007) 1172-1184
59. Knobloch M., Konietzko U., Krebs D.C., and Nitsch R.M. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 28 (2007) 1297-1306
60. Stern E.A., Bacskai B.J., Hickey G.A., Attenello F.J., Lombardo J.A., and Hyman B.T. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci 24 (2004) 4535-4540
61. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004) 306-319